Abstract
The novel carbocyclic nucleoside, abacavir, is metabolized in cells to carbovir triphosphate which is a potent inhibitor of HIV reverse transcriptase (Ki 0.021 μM with calf thymus DNA template primer). Abacavir exhibits potent in vitro antiviral activity against wild-type HIV-1 (IC50 4.0 μM, MT-4 cells) but this activity is lower than the activity of AZT (IC50 0.040 μM, MT-4 cells). However, there is no significant difference between the levels of activity of abacavir (IC50 0.26 μM) and AZT (IC50 0.23 μM) against clinical isolates of HIV-1. The in vitro toxicity data (CC50) of abacavir were: 160 μM (CEM cells); 140 μM (CD4+ CEM cells) and 110 μM (normal bone progenitor cells, BFU-E). Abacavir has been approved in the United States for the treatment of pediatric and adult HIV infection and current recommendations consist of combination therapy in children with HIV infection. Resistance to abacavir develops relatively slowly, with most of the mutations conferring minimal resistance. The M184V mutation appears to be the cornerstone of higher level resistance in regimens containing abacavir, imparting a 2-4 fold reduction in the susceptibility of HIV to abacavir.
Keywords: abacavir, reverse transcriptase inhibitor, combination therapy, resistance, pediatric hiv
Current Pharmaceutical Design
Title: The Antiviral Activity, Mechanism of Action, Clinical Significance and Resistance of Abacavir in the Treatment of Pediatric AIDS
Volume: 11 Issue: 29
Author(s): J. Melroy and V. Nair
Affiliation:
Keywords: abacavir, reverse transcriptase inhibitor, combination therapy, resistance, pediatric hiv
Abstract: The novel carbocyclic nucleoside, abacavir, is metabolized in cells to carbovir triphosphate which is a potent inhibitor of HIV reverse transcriptase (Ki 0.021 μM with calf thymus DNA template primer). Abacavir exhibits potent in vitro antiviral activity against wild-type HIV-1 (IC50 4.0 μM, MT-4 cells) but this activity is lower than the activity of AZT (IC50 0.040 μM, MT-4 cells). However, there is no significant difference between the levels of activity of abacavir (IC50 0.26 μM) and AZT (IC50 0.23 μM) against clinical isolates of HIV-1. The in vitro toxicity data (CC50) of abacavir were: 160 μM (CEM cells); 140 μM (CD4+ CEM cells) and 110 μM (normal bone progenitor cells, BFU-E). Abacavir has been approved in the United States for the treatment of pediatric and adult HIV infection and current recommendations consist of combination therapy in children with HIV infection. Resistance to abacavir develops relatively slowly, with most of the mutations conferring minimal resistance. The M184V mutation appears to be the cornerstone of higher level resistance in regimens containing abacavir, imparting a 2-4 fold reduction in the susceptibility of HIV to abacavir.
Export Options
About this article
Cite this article as:
Melroy J. and Nair V., The Antiviral Activity, Mechanism of Action, Clinical Significance and Resistance of Abacavir in the Treatment of Pediatric AIDS, Current Pharmaceutical Design 2005; 11 (29) . https://dx.doi.org/10.2174/138161205774580642
DOI https://dx.doi.org/10.2174/138161205774580642 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research Glycosidated Phospholipids – a Promising Group of Anti-Tumour Lipids
Anti-Cancer Agents in Medicinal Chemistry What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Microwave Assisted Synthesis of Coumarins: A Review From 2007 to 2018
Current Microwave Chemistry Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)
Current Medicinal Chemistry COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses The Role of Scaffolding in Standard Mechanism Serine Proteinase Inhibitors
Protein & Peptide Letters Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Current Pharmaceutical Design Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition